{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"125","value":"379"},{"groupId":"OG001","spread":"129","value":"390"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"394"},{"groupId":"OG001","value":"309"}],"units":"Participants"}],"description":"Maximum atezolizumab serum concentration.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).","id":"OG000","title":"Atezolizumab+Gemcitabine+Carboplatin/Cisplatin"},{"description":"Eligible participants received open-label atezolizumab as monotherapy.","id":"OG001","title":"Atezolizumab Monotherapy"}],"paramType":"MEAN","populationDescription":"The pharmacokinetic (PK)-evaluable population is defined as all participants dosed with atezolizumab who have at least one post-baseline PK result.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1","title":"Maximum Atezolizumab Serum Concentration","type":"SECONDARY","unitOfMeasure":"μg/ mL"}